Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.63 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1027480 | 0.98 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL3285142 | 0.95 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL27842525 | 0.93 | TAAR1 (0.74) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL3285178 | 0.93 | TAAR1 (0.74) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL7745905 | 0.90 | MAOB (0.65) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL42400 | 0.89 | TAAR1 (1.00) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL29986862 | 0.88 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002016 | 0.88 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002162 | 0.88 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| Hydrochloric Acid SCHEMBL10917318 | 0.87 | TAAR1 (0.96) | TAAR1CHRM2CHRM1CHRM3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745718-B | Preparation method of delta-hydroxy substituted aromatic acetonitrile derivative | 浙江工业大学台州研究院 | 2024-02-13 | — | — | CN | disclosed |
| CN-109219604-B | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3440067-B1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-3440067-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Hoffmann-La Roche AG (CH) | 2019-02-13 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| CN-109219604-A | Tetrahydroisoquinoline estrogenic agents and application thereof | 豪夫迈·罗氏有限公司 | 2019-01-15 | — | — | CN | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9969732-B2 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024653-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| CN-1329605-A | Benzofuran derivatives their preparation and use | LUNDBECK & CO AS H (DK) | 2002-01-02 | — | — | CN | disclosed |
| EP-0525360-B1 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1998-03-25 | — | — | EP | disclosed |
| US-5661185-A | AN ALKOXYPHENYL-ALKYLUREA COMPOUND TREATING SLEEP DISORDER | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5541228-A | Melatonergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0706994-A1 | Melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5242944-A | Analgesics or antiinflammatory agents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-09-07 | — | — | US | disclosed |
| EP-0525360-A2 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0007716-A1 | R-N-(2-phenyl-2-hydroxyethyl)-3-phenylpropyl amines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | TAAR1 1029/4885CHRM2 20/4885CHRM1 23/4885 |
| US-20170320871-A1 | TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | TAAR1 668/4885CHRM2 444/4885CHRM1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.